Andexanet Alfa Use in Patients Requiring Cardiopulmonary Bypass: Quo Vadis?
Publication
, Journal Article
Levy, JH; Welsby, I
Published in: A A Pract
December 15, 2019
Duke Scholars
Published In
A A Pract
DOI
EISSN
2575-3126
Publication Date
December 15, 2019
Volume
13
Issue
12
Start / End Page
477
Location
United States
Related Subject Headings
- Recombinant Proteins
- Pyridones
- Pyrazoles
- Patients
- Humans
- Factor Xa
- Cardiopulmonary Bypass
Citation
APA
Chicago
ICMJE
MLA
NLM
Levy, J. H., & Welsby, I. (2019). Andexanet Alfa Use in Patients Requiring Cardiopulmonary Bypass: Quo Vadis? A A Pract, 13(12), 477. https://doi.org/10.1213/XAA.0000000000001115
Levy, Jerrold H., and Ian Welsby. “Andexanet Alfa Use in Patients Requiring Cardiopulmonary Bypass: Quo Vadis?” A A Pract 13, no. 12 (December 15, 2019): 477. https://doi.org/10.1213/XAA.0000000000001115.
Levy JH, Welsby I. Andexanet Alfa Use in Patients Requiring Cardiopulmonary Bypass: Quo Vadis? A A Pract. 2019 Dec 15;13(12):477.
Levy, Jerrold H., and Ian Welsby. “Andexanet Alfa Use in Patients Requiring Cardiopulmonary Bypass: Quo Vadis?” A A Pract, vol. 13, no. 12, Dec. 2019, p. 477. Pubmed, doi:10.1213/XAA.0000000000001115.
Levy JH, Welsby I. Andexanet Alfa Use in Patients Requiring Cardiopulmonary Bypass: Quo Vadis? A A Pract. 2019 Dec 15;13(12):477.
Published In
A A Pract
DOI
EISSN
2575-3126
Publication Date
December 15, 2019
Volume
13
Issue
12
Start / End Page
477
Location
United States
Related Subject Headings
- Recombinant Proteins
- Pyridones
- Pyrazoles
- Patients
- Humans
- Factor Xa
- Cardiopulmonary Bypass